US1391707A
(en)
|
1918-08-15 |
1921-09-27 |
Viviano Philip |
Automatic change-speed transmission
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
US4331647A
(en)
|
1980-03-03 |
1982-05-25 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
|
US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
US4411993A
(en)
|
1981-04-29 |
1983-10-25 |
Steven Gillis |
Hybridoma antibody which inhibits interleukin 2 activity
|
US4427115A
(en)
|
1981-10-19 |
1984-01-24 |
Laipply Thomas C |
One piece alcohol preparation device
|
USRE32011E
(en)
|
1981-12-14 |
1985-10-22 |
Scripps Clinic And Research Foundation |
Ultrapurification of factor VIII using monoclonal antibodies
|
EP0088046B1
(de)
|
1982-02-17 |
1987-12-09 |
Ciba-Geigy Ag |
Lipide in wässriger Phase
|
US4543439A
(en)
|
1982-12-13 |
1985-09-24 |
Massachusetts Institute Of Technology |
Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
US6054561A
(en)
|
1984-02-08 |
2000-04-25 |
Chiron Corporation |
Antigen-binding sites of antibody molecules specific for cancer antigens
|
DE3417525C1
(de)
|
1984-05-11 |
1986-01-09 |
Matter + Siegmann Ag, Wohlen |
Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
|
US4902614A
(en)
|
1984-12-03 |
1990-02-20 |
Teijin Limited |
Monoclonal antibody to human protein C
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5571714A
(en)
|
1988-12-22 |
1996-11-05 |
Celtrix Pharmaceuticals, Inc. |
Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5549910A
(en)
|
1989-03-31 |
1996-08-27 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
US5177197A
(en)
|
1990-02-27 |
1993-01-05 |
Ludwig Institute For Cancer Research |
Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
|
US5466468A
(en)
|
1990-04-03 |
1995-11-14 |
Ciba-Geigy Corporation |
Parenterally administrable liposome formulation comprising synthetic lipids
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
JP3218637B2
(ja)
|
1990-07-26 |
2001-10-15 |
大正製薬株式会社 |
安定なリポソーム水懸濁液
|
WO1992002551A1
(en)
|
1990-08-02 |
1992-02-20 |
B.R. Centre Limited |
Methods for the production of proteins with a desired function
|
JP2958076B2
(ja)
|
1990-08-27 |
1999-10-06 |
株式会社ビタミン研究所 |
遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5698426A
(en)
|
1990-09-28 |
1997-12-16 |
Ixsys, Incorporated |
Surface expression libraries of heteromeric receptors
|
JPH04141095A
(ja)
|
1990-10-02 |
1992-05-14 |
Chemo Sero Therapeut Res Inst |
組換え抗hiv改変抗体および改変抗体の調製方法
|
US5070108A
(en)
|
1990-10-12 |
1991-12-03 |
Trustees Of The University Of Pennsylvania |
Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
|
AU662304B2
(en)
|
1990-10-22 |
1995-08-31 |
Fox Chase Cancer Center |
DNA construct for providing RNA therapy
|
US5399363A
(en)
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
DE122009000019I1
(de)
|
1991-04-25 |
2009-07-16 |
Chugai Seiyaku K K 5 1 |
Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
|
CA2164505A1
(en)
|
1993-06-07 |
1994-12-22 |
Phillip W. Berman |
Hiv envelope polypeptides
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
US5453492A
(en)
|
1993-07-28 |
1995-09-26 |
La Jolla Cancer Research Foundation |
60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
AU702163B2
(en)
|
1994-04-29 |
1999-02-18 |
Creative Biomolecules, Inc. |
Morphogenic protein-specific cell surface receptors and uses therefor
|
DE4427221A1
(de)
|
1994-08-01 |
1996-02-08 |
Gsf Forschungszentrum Umwelt |
Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
|
US5846770A
(en)
|
1994-11-22 |
1998-12-08 |
Genetics Institute, Inc. |
DNA molecules encoding human chordin
|
US6057421A
(en)
|
1994-11-30 |
2000-05-02 |
Immpheron, Inc. |
Variable heavy and light chain regions of murine monoclonal antibody 1F7
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
IE80468B1
(en)
|
1995-04-04 |
1998-07-29 |
Elan Corp Plc |
Controlled release biodegradable nanoparticles containing insulin
|
CA2220912A1
(en)
|
1995-06-05 |
1996-12-12 |
Gregg A. Hastings |
Human ccn-like growth factor
|
US5738868A
(en)
|
1995-07-18 |
1998-04-14 |
Lipogenics Ltd. |
Liposome compositions and kits therefor
|
BR9710811A
(pt)
|
1996-05-22 |
1999-08-17 |
Novopharm Biotech Inc |
Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
US5989909A
(en)
|
1997-09-26 |
1999-11-23 |
Millennium Biotherapeutics, Inc. |
Huchordin and uses thereof
|
WO1998046588A2
(en)
|
1997-04-11 |
1998-10-22 |
Neorx Corporation |
Compounds and therapies for the prevention of vascular and non-vascular pathologies
|
JP3614866B2
(ja)
|
1997-06-12 |
2005-01-26 |
リサーチ コーポレイション テクノロジーズ,インコーポレイティド |
人工抗体ポリペプチド
|
US6075007A
(en)
|
1997-07-17 |
2000-06-13 |
Regeneron Pharmaceuticals, Inc. |
Modified noggin polypeptide and compositions
|
CA2297109A1
(en)
|
1997-08-01 |
1999-02-11 |
Genset |
5' ests for secreted proteins expressed in muscle and other mesodermal tissues
|
US6815201B2
(en)
|
1997-09-08 |
2004-11-09 |
The Public Health Research Institute Of The City Of New York, Inc. |
HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
|
US6544485B1
(en)
|
2001-01-29 |
2003-04-08 |
Sharper Image Corporation |
Electro-kinetic device with enhanced anti-microorganism capability
|
NZ552959A
(en)
|
1998-11-27 |
2008-06-30 |
Darwin Discovery Ltd |
Compositions and methods for increasing bone mineralization
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
IL144578A0
(en)
|
1999-01-29 |
2002-05-23 |
Imclone Systems Inc |
Antibodies specific to kdr and uses thereof
|
JP2003501087A
(ja)
|
1999-06-09 |
2003-01-14 |
ジェネンテック・インコーポレーテッド |
腫瘍の治療のための組成物と方法
|
JP4141095B2
(ja)
|
1999-10-29 |
2008-08-27 |
三洋電機株式会社 |
半導体装置とその製造方法
|
MXPA02008506A
(es)
|
2000-03-02 |
2002-12-13 |
Amgen Inc |
Moleculas semejantes a chordin-2 y sus usos.
|
AU2001265198A1
(en)
|
2000-06-01 |
2001-12-11 |
Amgen Inc. |
Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
|
CA2412110A1
(en)
|
2000-06-19 |
2001-12-27 |
F. Hoffmann-La Roche Ag |
Osteolevin gene polymorphisms
|
AU2002216610A1
(en)
|
2000-09-01 |
2002-04-02 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
AU1344102A
(en)
|
2000-10-12 |
2002-04-22 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
CA2374027A1
(en)
|
2001-03-13 |
2002-09-13 |
The Minister Of National Defence |
Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
|
DE10145772A1
(de)
|
2001-09-17 |
2003-04-10 |
Bayer Cropscience Ag |
DELTA·1·-Pyrroline
|
BRPI0214680B1
(pt)
|
2001-12-06 |
2018-09-18 |
Biocontrol Systems Inc |
instrumento para uso em monitorar um produto, um ingrediente, um ambiente ou processo, instrumento para detectar emissão de luz de uma amostra e método de monitorar uma amostra de um produto, um ingrediente, um processo ou ambiente
|
US20030186915A1
(en)
|
2002-02-11 |
2003-10-02 |
Yang Pan |
Regulatory polynucleotides and uses thereof
|
US7332276B2
(en)
|
2002-03-01 |
2008-02-19 |
Celltech R&D, Inc. |
Methods to increase or decrease bone density
|
AU2003221841A1
(en)
|
2002-04-03 |
2003-10-27 |
Celltech R And D, Inc. |
Association of polymorphisms in the sost gene region with bone mineral density
|
US7893218B2
(en)
|
2003-06-16 |
2011-02-22 |
Stowers Institute For Medical Research |
Antibodies that specifically bind SOST peptides
|
AU2003276430A1
(en)
|
2002-06-14 |
2003-12-31 |
Stowers Institute For Medical Research |
Wise/sost nucleic acid sequences and amino acid sequences
|
WO2004098491A2
(en)
|
2002-11-01 |
2004-11-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
|
US7642238B2
(en)
|
2002-12-05 |
2010-01-05 |
Shaughnessy John D |
Molecular determinants of myeloma bone disease and uses thereof
|
US20040141875A1
(en)
|
2003-01-15 |
2004-07-22 |
Rajiv Doshi |
System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
|
WO2004082608A2
(en)
|
2003-03-14 |
2004-09-30 |
Celltech R & D, Inc. |
Ligands for tgf-beta binding proteins and uses thereof
|
US20050158303A1
(en)
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
CU23403A1
(es)
|
2003-04-23 |
2009-08-04 |
Centro Inmunologia Molecular |
Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
|
EP1636270B1
(en)
|
2003-06-16 |
2016-07-20 |
UCB Pharma S.A. |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
US8461155B2
(en)
|
2003-09-22 |
2013-06-11 |
University Of Connecticut |
Sclerostin and the inhibition of WNT signaling and bone formation
|
US20050267233A1
(en)
|
2004-05-25 |
2005-12-01 |
Joshi Ashok V |
Anti-microbial handle system
|
AU2005267722B2
(en)
|
2004-08-04 |
2009-10-08 |
Amgen Inc. |
Antibodies to Dkk-1
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
EP1981910B1
(en)
|
2006-01-13 |
2013-06-26 |
A Chan Holding B.V. |
Method for identifying inhibitor of the glypican-sclerostin interaction
|
WO2008061013A2
(en)
|
2006-11-10 |
2008-05-22 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
US20100015665A1
(en)
|
2006-11-10 |
2010-01-21 |
Ucb Pharma S.A. |
Antibodies and diagnostics
|
EP2144613B1
(en)
|
2006-12-29 |
2018-03-21 |
OstéoQC Inc. |
Methods of altering bone growth by administration of sost or wise antagonist or agonist
|
WO2008092894A1
(en)
|
2007-02-02 |
2008-08-07 |
Novartis Ag |
Modulators of sclerostin binding partners for treating bone-related disorders
|
US7744874B2
(en)
|
2007-03-20 |
2010-06-29 |
Eli Lilly And Company |
Anti-sclerostin antibodies
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
EP2031064A1
(de)
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
CL2008002775A1
(es)
*
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
PL2567709T3
(pl)
|
2007-11-02 |
2018-06-29 |
Novartis Ag |
Cząsteczki i sposoby modulowania białka związanego z receptorem dla lipoproteiny o niskiej gęstości 6 (LRP6)
|
CA2707400A1
(en)
|
2007-12-14 |
2009-06-25 |
Amgen Inc. |
Method for treating bone fracture with anti-sclerostin antibodies
|
JP2011523853A
(ja)
|
2008-06-03 |
2011-08-25 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリン及びその使用
|
WO2010100179A2
(en)
|
2009-03-05 |
2010-09-10 |
Novartis Ag |
Self-forming gel system for sustained drug delivery
|
AR075715A1
(es)
|
2009-03-05 |
2011-04-20 |
Novartis Ag |
Formulacion de anticuerpo liofilizado
|
WO2010115932A1
(en)
|
2009-04-08 |
2010-10-14 |
Novartis Ag |
Combination for the treatment of bone loss
|
WO2010130830A2
(en)
|
2009-05-15 |
2010-11-18 |
Ablynx N.V. |
Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
|
DK3195880T3
(da)
*
|
2010-05-14 |
2020-03-02 |
Amgen Inc |
Højkoncentrerede anti-sclerostin-antistofformuleringer
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
EP2632951B1
(en)
|
2010-10-27 |
2017-08-02 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
WO2013004841A1
(en)
|
2011-07-06 |
2013-01-10 |
Genmab A/S |
Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
|
WO2014159579A1
(en)
*
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
KR20190096409A
(ko)
|
2016-12-21 |
2019-08-19 |
메레오 바이오파마 3 리미티드 |
불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도
|